Active substances
Potassium bicarbonate + Sodium alginate
- SFDA 3
- NHS prices 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| GAVISCON ADVANCE PEPPERMINT FLAVOR ORAL SUSPENSION | 500,100 mg,mg | Oral suspension · Oral use | 1 Bottle | SAR 26.70 | Generic · OTC | RECKITT BENCKISER HEALTHCARE COMPANY | Valid |
| GAVISCON ADVANCE PEPPERMINT LIQUID SACHET | 500,100 mg,mg | Oral suspension · Oral use | 24 Sachet | SAR 30.40 | Generic · OTC | RECKITT BENCKISER | Valid |
| GAVISCON ADVANCE PEPPERMINT LIQUID SACHET | 500,100 mg,mg | Oral suspension · Oral use | 12 Sachet | SAR 15.20 | Generic · OTC | RECKITT BENCKISER | Valid |
Indications — CHI Daman Drug Formulary
ANESTHESIA-SUPPORTIVE AGENTS/ ASPIRATION PNEUMONIA PROPHYLAXIS; GASTROESOPHAGEAL REFLUX DISEASE (GERD)
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Sodium alginate 500mg / Potassium bicarbonate 100mg chewable tablets sugar free | £6.32 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Sodium alginate 500mg/5ml / Potassium bicarbonate 100mg/5ml oral suspension sugar free | £5.50 | 150 ml | 1 Oct 2026 |
| NHS Drug Tariff | Sodium alginate 500mg/5ml / Potassium bicarbonate 100mg/5ml oral suspension sugar free | £4.58 | 250 ml | 1 Oct 2026 |
| NHS Drug Tariff | Sodium alginate 500mg/5ml / Potassium bicarbonate 100mg/5ml oral suspension sugar free | £9.17 | 500 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.